ClinicalTrials.Veeva

Menu

Assessment of the Impact of Gadolinium Injection on the Measurement of the QSM Signal (GADO-QSM)

F

Fondation Ophtalmologique Adolphe de Rothschild

Status

Completed

Conditions

White Matter Disease

Treatments

Device: MRI

Study type

Observational

Funder types

NETWORK

Identifiers

NCT04906941
JSY_2021_14

Details and patient eligibility

About

Patients meeting the inclusion and non-inclusion criteria will be offered to participate in the study. If they agree, they will perform an MRI without injection to obtain the QSM then perform the MRI with injection that was prescribed to them as part of the care, then they will perform a second time the MRI without injection to obtain the QSM. They will also answer a short questionnaire documenting their previous exposure to gadolinium.

Full description

Patients meeting the inclusion and non-inclusion criteria will be offered to participate in the study. If they agree, they will perform an MRI without injection to obtain the QSM then perform the MRI with injection that was prescribed to them as part of the care, then they will perform a second time the MRI without injection to obtain the QSM. They will also answer a short questionnaire documenting their previous exposure to gadolinium.

Enrollment

73 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients over 18 years old
  • with an inflammatory CNS pathology
  • to benefit as part of care from an MRI with injection of gadolinium
  • consent to participate in the study
  • beneficiary of a social protection scheme

Exclusion criteria

  • pregnant or breastfeeding woman
  • patient benefiting from a legal protection measure
  • Patient having performed more than 3 MRI exams with gadolinium injection during his life

Secondary exclusion criteria :

  • motion artifact not allowing image interpretation
  • patient who has not completed one of the following sequences: T1 anatomical, FLAIR, or QSM pre-gadolinium injection.

Secondarily excluded patients will be replaced up to a maximum of 25 patients.

Trial contacts and locations

1

Loading...

Central trial contact

amélie YAVCHITZ

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems